

# Annamaria Colao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/950476/publications.pdf>

Version: 2024-02-01

429  
papers

22,895  
citations

8159

76  
h-index

15683

125  
g-index

446  
all docs

446  
docs citations

446  
times ranked

17907  
citing authors

#	ARTICLE	IF	CITATIONS
1	Coffee consumption, health benefits and side effects: a narrative review and update for dietitians and nutritionists. <i>Critical Reviews in Food Science and Nutrition</i> , 2023, 63, 1238-1261.	5.4	24
2	Nutritional management of type 2 diabetes in subjects with obesity: an international guideline for clinical practice. <i>Critical Reviews in Food Science and Nutrition</i> , 2023, 63, 2873-2885.	5.4	11
3	A practical nutritional guideline to manage neuroendocrine neoplasms through chronotype and sleep. <i>Critical Reviews in Food Science and Nutrition</i> , 2023, 63, 7546-7563.	5.4	1
4	Could very low-calorie ketogenic diets turn off low grade inflammation in obesity? Emerging evidence. <i>Critical Reviews in Food Science and Nutrition</i> , 2023, 63, 8320-8336.	5.4	17
5	Clinical and nutritional management of very-low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: a practical guide for the nutritionist. <i>Critical Reviews in Food Science and Nutrition</i> , 2023, 63, 10775-10791.	5.4	12
6	Ketogenic diet: a tool for the management of neuroendocrine neoplasms?. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 1035-1045.	5.4	9
7	Could ketogenic diet "starve" cancer? Emerging evidence. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 1800-1821.	5.4	39
8	Very low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: an update for dermatologists and nutritionists. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 398-414.	5.4	32
9	Nutritional guidelines for the management of insulin resistance. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 6947-6960.	5.4	23
10	Cut-off for the Mediterranean diet score to identify subjects with morning chronotype in middle-aged Italian adults. <i>Minerva Endocrinology</i> , 2022, 47, .	0.6	3
11	Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors. <i>Endocrine</i> , 2022, 75, 623-634.	1.1	6
12	The clock diet: a practical nutritional guide to manage obesity through chrononutrition. <i>Minerva Medica</i> , 2022, 113, .	0.3	11
13	Is there a relationship between the ketogenic diet and sleep disorders?. <i>International Journal of Food Sciences and Nutrition</i> , 2022, 73, 285-295.	1.3	13
14	Canine insulinoma as a model for human malignant insulinoma research: Novel perspectives for translational clinical studies. <i>Translational Oncology</i> , 2022, 15, 101269.	1.7	8
15	VLCKD: a real time safety study in obesity. <i>Journal of Translational Medicine</i> , 2022, 20, 23.	1.8	26
16	Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition. <i>International Journal of Obesity</i> , 2022, 46, 449-465.	1.6	65
17	Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 941-961.	1.8	6
18	Obesity and Thyroid Cancer Risk: An Update. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1116.	1.2	32

#	ARTICLE	IF	CITATIONS
19	Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric caseâ€“control study. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 849-857.	1.8	27
20	Treatment of Paget's disease of the bone: long-term effect of neridronate in a real-life setting. <i>Minerva Endocrinology</i> , 2022, 46, 374-383.	0.6	0
21	Sarcopenic obesity: What about in the cancer setting?. <i>Nutrition</i> , 2022, 98, 111624.	1.1	14
22	Chronotype: A Tool to Screen Eating Habits in Polycystic Ovary Syndrome?. <i>Nutrients</i> , 2022, 14, 955.	1.7	11
23	Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?. <i>Journal of Clinical Medicine</i> , 2022, 11, 1019.	1.0	5
24	Prognostic significance of laterality in lung neuroendocrine tumors. <i>Endocrine</i> , 2022, 76, 733-746.	1.1	8
25	Dietary Recommendations for Post-COVID-19 Syndrome. <i>Nutrients</i> , 2022, 14, 1305.	1.7	26
26	Anti-Inflammatory Nutrients and Obesity-Associated Metabolic-Inflammation: State of the Art and Future Direction. <i>Nutrients</i> , 2022, 14, 1137.	1.7	49
27	Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience. <i>Frontiers in Neurology</i> , 2022, 13, 783737.	1.1	1
28	Low-grade inflammation, CoVID-19, and obesity: clinical aspect and molecular insights in childhood and adulthood. <i>International Journal of Obesity</i> , 2022, 46, 1254-1261.	1.6	12
29	An unusual case report of polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2022, , 1.	1.8	0
30	Gestational obesity: An unconventional endocrine disruptor for the fetus. <i>Biochemical Pharmacology</i> , 2022, 198, 114974.	2.0	3
31	Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe. <i>European Journal of Endocrinology</i> , 2022, 186, K17-K24.	1.9	7
32	The role of outdoor and indoor air quality in the spread of SARS-CoV-2: Overview and recommendations by the research group on COVID-19 and particulate matter (RESCOP commission). <i>Environmental Research</i> , 2022, 211, 113038.	3.7	42
33	The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review. <i>Obesity Reviews</i> , 2022, 23, e13390.	3.1	18
34	Insulin-like growth factor-1 (IGF-1) as predictor of cardiovascular mortality in heart failure patients: data from the T.O.S.CA. registry. <i>Internal and Emergency Medicine</i> , 2022, 17, 1651-1660.	1.0	4
35	Vitamin D: A Role Also in Long COVID-19?. <i>Nutrients</i> , 2022, 14, 1625.	1.7	34
36	Mediterranean Diet: What Are the Consequences for Menopause?. <i>Frontiers in Endocrinology</i> , 2022, 13, 886824.	1.5	6

#	ARTICLE	IF	CITATIONS
37	From the Ketogenic Diet to the Mediterranean Diet: The Potential Dietary Therapy in Patients with Obesity after CoVID-19 Infection (Post CoVID Syndrome). <i>Current Obesity Reports</i> , 2022, , .	3.5	10
38	Updating obesity management strategies: an audit of Italian specialists. <i>Eating and Weight Disorders</i> , 2022, 27, 2653-2663.	1.2	1
39	“Planeterranean” Diet: extending worldwide the health benefits of Mediterranean Diet based on nutritional properties of locally available foods. <i>Journal of Translational Medicine</i> , 2022, 20, 232.	1.8	10
40	From Gut Microbiota through Low-Grade Inflammation to Obesity: Key Players and Potential Targets. <i>Nutrients</i> , 2022, 14, 2103.	1.7	29
41	Prognostic Effect of Lymph Node Metastases and Mesenteric Deposits in Neuroendocrine Tumors of the Small Bowel. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 3209-3221.	1.8	1
42	Phase angle as an easy diagnostic tool for the nutritionist in the evaluation of inflammatory changes during the active stage of a very low-calorie ketogenic diet. <i>International Journal of Obesity</i> , 2022, 46, 1591-1597.	1.6	22
43	Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 389-403.	1.2	11
44	PRRT: identikit of the perfect patient. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 563-579.	2.6	14
45	Nutrition and immune system: from the Mediterranean diet to dietary supplementary through the microbiota. <i>Critical Reviews in Food Science and Nutrition</i> , 2021, 61, 3066-3090.	5.4	83
46	Improving sleep disturbances in obesity by nutritional strategies: review of current evidence and practical guide. <i>International Journal of Food Sciences and Nutrition</i> , 2021, 72, 579-591.	1.3	17
47	Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?. <i>Neuroendocrinology</i> , 2021, 111, 1066-1085.	1.2	85
48	From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 511-525.	2.6	13
49	Mediterranean diet as medical prescription in menopausal women with obesity: a practical guide for nutritionists. <i>Critical Reviews in Food Science and Nutrition</i> , 2021, 61, 1201-1211.	5.4	33
50	The opera prevention project. <i>International Journal of Food Sciences and Nutrition</i> , 2021, 72, 1-3.	1.3	24
51	Nutritional status and follicular-derived thyroid cancer: An update. <i>Critical Reviews in Food Science and Nutrition</i> , 2021, 61, 25-59.	5.4	57
52	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , 2021, 53, 367-374.	0.4	12
53	A practical nutritional guide for the management of sleep disturbances in menopause. <i>International Journal of Food Sciences and Nutrition</i> , 2021, 72, 432-446.	1.3	11
54	Quality of Life in Patients with Neuroendocrine Neoplasms: The Role of Severity, Clinical Heterogeneity, and Resilience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e316-e327.	1.8	21

#	ARTICLE	IF	CITATIONS
55	Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 957-968.	1.8	13
56	Characterization with hybrid imaging of cystic pheochromocytomas: correlation with pathology. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 862-869.	1.1	5
57	Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.C.A. Registry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1691-1700.	0.8	26
58	Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. <i>Frontiers in Endocrinology</i> , 2021, 12, 649496.	1.5	27
59	The impact of obesity on immune response to infection: Plausible mechanisms and outcomes. <i>Obesity Reviews</i> , 2021, 22, e13216.	3.1	33
60	Phase Angle as an Easy Diagnostic Tool of Meta-Inflammation for the Nutritionist. <i>Nutrients</i> , 2021, 13, 1446.	1.7	42
61	Phase angle and Mediterranean diet in patients with acne: Two easy tools for assessing the clinical severity of disease. <i>Journal of Translational Medicine</i> , 2021, 19, 171.	1.8	14
62	Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications. <i>Frontiers in Endocrinology</i> , 2021, 12, 665631.	1.5	7
63	An Italian Survey on Dietary Habits and Changes during the COVID-19 Lockdown. <i>Nutrients</i> , 2021, 13, 1197.	1.7	54
64	What about Mediterranean diet as tool to improve sleep quality in obesity?. <i>Minerva Endocrinology</i> , 2021, , .	0.6	4
65	Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?. <i>Frontiers in Endocrinology</i> , 2021, 12, 667784.	1.5	13
66	Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel. <i>Endocrine</i> , 2021, 72, 597-603.	1.1	24
67	Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2845-2847.	1.8	21
68	Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers. <i>Frontiers in Endocrinology</i> , 2021, 12, 665698.	1.5	9
69	Association of the Chronotype Score with Circulating Trimethylamine N-Oxide (TMAO) Concentrations. <i>Nutrients</i> , 2021, 13, 1671.	1.7	11
70	Vitamin D in obesity and obesity-related diseases: an overview. <i>Minerva Endocrinology</i> , 2021, 46, 177-192.	0.6	41
71	Association of Trimethylamine N-Oxide (TMAO) with the Clinical Severity of Hidradenitis Suppurativa (Acne Inversa). <i>Nutrients</i> , 2021, 13, 1997.	1.7	8
72	Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. <i>Frontiers in Endocrinology</i> , 2021, 12, 700806.	1.5	2

#	ARTICLE	IF	CITATIONS
73	Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches. <i>Frontiers in Endocrinology</i> , 2021, 12, 651438.	1.5	13
74	Editorialâ€™Special Issue: Foreword to the Special Issue on NIKE: Neuroendocrine Tumors, Innovation in Knowledge and Education. <i>Frontiers in Endocrinology</i> , 2021, 12, 722145.	1.5	1
75	Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?. <i>Journal of Translational Medicine</i> , 2021, 19, 324.	1.8	13
76	Vitamin D Fortification of Consumption Cowâ€™s Milk: Health, Nutritional and Technological Aspects. A Multidisciplinary Lecture of the Recent Scientific Evidence. <i>Molecules</i> , 2021, 26, 5289.	1.7	6
77	The role of the nurse in the Obesity Clinic: a practical guideline. <i>Panminerva Medica</i> , 2021, 63, .	0.2	2
78	Hyperprolactinemia after menopause: Diagnosis and management. <i>Maturitas</i> , 2021, 151, 36-40.	1.0	4
79	Craniopharyngioma, Chronotypes and Metabolic Risk Profile. <i>Nutrients</i> , 2021, 13, 3444.	1.7	2
80	Magnetic resonance imaging is a valuable tool to evaluate the therapeutic efficacy of burosumab in children with X-linked hypophosphatemia. <i>European Journal of Endocrinology</i> , 2021, 185, 475-484.	1.9	4
81	PCOS and nutritional approaches: Differences between lean and obese phenotype. <i>Metabolism Open</i> , 2021, 12, 100123.	1.4	29
82	Papillary thyroid carcinoma arising in ectopic thyroid tissue within sternocleidomastoid muscle: a review of current literature. <i>Minerva Endocrinologica</i> , 2021, 45, 318-325.	1.7	5
83	European Guidelines for Obesity Management in Adults with a Very Low-Calorie Ketogenic Diet: A Systematic Review and Meta-Analysis. <i>Obesity Facts</i> , 2021, 14, 222-245.	1.6	112
84	Diet as a possible influencing factor in thyroid cancer incidence: the point of view of the nutritionist. <i>Panminerva Medica</i> , 2021, 63, 349-360.	0.2	9
85	Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks. <i>Journal of Clinical Medicine</i> , 2021, 10, 88.	1.0	19
86	Metabolically Healthy Obesity (MHO) vs. Metabolically Unhealthy Obesity (MUO) Phenotypes in PCOS: Association with Endocrine-Metabolic Profile, Adherence to the Mediterranean Diet, and Body Composition. <i>Nutrients</i> , 2021, 13, 3925.	1.7	33
87	Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment. <i>Frontiers in Endocrinology</i> , 2021, 12, 769744.	1.5	8
88	â€™Forever young at the tableâ€™: metabolic effects of eating speed in obesity. <i>Journal of Translational Medicine</i> , 2021, 19, 530.	1.8	5
89	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. <i>Annals of Surgery</i> , 2020, 271, 527-533.	2.1	44
90	Breast cancer prevention in premenopausal women: role of the Mediterranean diet and its components. <i>Nutrition Research Reviews</i> , 2020, 33, 19-32.	2.1	38

#	ARTICLE	IF	CITATIONS
91	Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors &lt; i> 2 Centimeters. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 78-84.	1.8	39
92	Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102840.	2.0	9
93	Vitamin D testing: advantages and limits of the current assays. <i>European Journal of Clinical Nutrition</i> , 2020, 74, 231-247.	1.3	81
94	Evaluation of < i> BRAF< /i>, < i> RAS< /i>, < i> RET/PTC< /i>, and < i> PAX8/PPARg< /i> alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7â€ gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy. <i>Cancer Cytopathology</i> , 2020, 128, 107-118.	1.4	55
95	Mediterranean diet as tool to manage obesity in menopause: A narrative review. <i>Nutrition</i> , 2020, 79-80, 110991.	1.1	24
96	From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. <i>International Journal of Obesity Supplements</i> , 2020, 10, 35-49.	12.5	40
97	Nutrigeneticsâ€ personalized nutrition in obesity and cardiovascular diseases. <i>International Journal of Obesity Supplements</i> , 2020, 10, 1-13.	12.5	34
98	Sleep disturbances: one of the culprits of obesity-related cardiovascular risk?. <i>International Journal of Obesity Supplements</i> , 2020, 10, 62-72.	12.5	15
99	Phase Angle: Could Be an Easy Tool to Detect Low-Grade Systemic Inflammation in Adults Affected by Praderâ€ Willi Syndrome?. <i>Nutrients</i> , 2020, 12, 2065.	1.7	21
100	Editorial: Health-Related Complications of Acromegaly. <i>Frontiers in Endocrinology</i> , 2020, 11, 496.	1.5	1
101	Maternal obesity: focus on offspring cardiometabolic outcomes. <i>International Journal of Obesity Supplements</i> , 2020, 10, 27-34.	12.5	11
102	Does Sars-Cov-2 threaten our dreams? Effect of quarantine on sleep quality and body mass index. <i>Journal of Translational Medicine</i> , 2020, 18, 318.	1.8	91
103	Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3507.	1.0	17
104	Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1429-1445.	1.8	17
105	Influence of the Mediterranean Diet on 25-Hydroxyvitamin D Levels in Adults. <i>Nutrients</i> , 2020, 12, 1439.	1.7	32
106	Diagnosis of Flierâ€™s syndrome in a patient with nondiabetic hypoglycemia: a case report and critical appraisal of the literature. <i>Endocrine</i> , 2020, 69, 73-78.	1.1	4
107	Chronotype and Adherence to the Mediterranean Diet in Obesity: Results from the Opera Prevention Project. <i>Nutrients</i> , 2020, 12, 1354.	1.7	68
108	Sleep Quality in Obesity: Does Adherence to the Mediterranean Diet Matter?. <i>Nutrients</i> , 2020, 12, 1364.	1.7	74

#	ARTICLE	IF	CITATIONS
109	Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. <i>Endocrine</i> , 2020, 69, 441-450.	1.1	26
110	COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 654-656.	5.5	23
111	COVID-19: Time for Post-Exposure Prophylaxis?. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3997.	1.2	10
112	Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 599-612.	2.6	25
113	Italian doctors call for protecting healthcare workers and boosting community surveillance during covid-19 outbreak. <i>BMJ</i> , 2020, 368, m1254.	3.0	73
114	Pancreatic Neuroendocrine Neoplasms: Does Sex Matter?. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 631-641.	3.1	22
115	Pancreatic Neuroendocrine Tumors in patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences. <i>Neuroendocrinology</i> , 2020, 111, 696-704.	1.2	5
116	Rethinking the role of the school after COVID-19. <i>Lancet Public Health</i> , 2020, 5, e370.	4.7	99
117	Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. <i>Frontiers in Oncology</i> , 2020, 10, 1047.	1.3	11
118	Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family. <i>Journal of Clinical Medicine</i> , 2020, 9, 588.	1.0	8
119	Sleep Apnea, Obesity, and Disturbed Glucose Homeostasis: Epidemiologic Evidence, Biologic Insights, and Therapeutic Strategies. <i>Current Obesity Reports</i> , 2020, 9, 30-38.	3.5	67
120	Searching for SARS-COV-2 on Particulate Matter: A Possible Early Indicator of COVID-19 Epidemic Recurrence. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2986.	1.2	99
121	Commentary: Obesity: The "Achilles heel" for COVID-19?. <i>Metabolism: Clinical and Experimental</i> , 2020, 108, 154251.	1.5	182
122	Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. <i>Nutrients</i> , 2020, 12, 1021.	1.7	17
123	The Sun's Vitamin in Adult Patients Affected by Prader-Willi Syndrome. <i>Nutrients</i> , 2020, 12, 1132.	1.7	9
124	Nutritional recommendations for CoVID-19 quarantine. <i>European Journal of Clinical Nutrition</i> , 2020, 74, 850-851.	1.3	353
125	Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia. <i>Endocrine Connections</i> , 2020, 9, 144-153.	0.8	30
126	Clinical pathological features, treatments and survival of malignant insulinomas: a multicenter study. <i>European Journal of Endocrinology</i> , 2020, 182, 439-446.	1.9	24



#	ARTICLE	IF	CITATIONS
127	Vitamin D and Sleep Regulation: Is there a Role for Vitamin D?. <i>Current Pharmaceutical Design</i> , 2020, 26, 2492-2496.	0.9	45
128	Bone metabolism, bone mass and structural integrity profile in professional male football players. <i>Journal of Sports Medicine and Physical Fitness</i> , 2020, 60, 912-918.	0.4	5
129	Specific cut-off for the 25-OH vitamin D levels to predict the highest Body Mass Index and fat mass: a sex-related analysis in obese patients. <i>Minerva Endocrinologica</i> , 2020, 45, 266-268.	1.7	13
130	New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. <i>Minerva Endocrinologica</i> , 2020, 45, 127-137.	1.7	24
131	Mediterranean diet and breast cancer risk: a narrative review. <i>Minerva Endocrinology</i> , 2020, , .	0.6	15
132	Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead. <i>Frontiers in Endocrinology</i> , 2020, 11, 604341.	1.5	27
133	Phase Angle: A Possible Biomarker to Quantify Inflammation in Subjects with Obesity and 25(OH)D Deficiency. <i>Nutrients</i> , 2019, 11, 1747.	1.7	60
134	Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?. <i>World Neurosurgery</i> , 2019, 127, 695-709.	0.7	16
135	The management of very low-calorie ketogenic diet in obesity outpatient clinic: a practical guide. <i>Journal of Translational Medicine</i> , 2019, 17, 356.	1.8	102
136	&lt;p&gt;Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy&lt;/p&gt;. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 525-537.	0.7	11
137	Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. <i>Cancers</i> , 2019, 11, 1332.	1.7	28
138	Somatotropic Axis and Obesity: Is There Any Role for the Mediterranean Diet?. <i>Nutrients</i> , 2019, 11, 2228.	1.7	27
139	Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS). <i>Nutrients</i> , 2019, 11, 2278.	1.7	162
140	Italian university rectors for health and environment: the U4ALL initiative. <i>Lancet, The</i> , 2019, 394, 1319.	6.3	1
141	Irritable bowel syndrome: a new therapeutic target when treating obesity?. <i>Hormones</i> , 2019, 18, 395-399.	0.9	19
142	Comment on "Acne and nutrition: hypotheses, myths and facts"™. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e418-e419.	1.3	3
143	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2019, 51, 1456-1460.	0.4	32
144	A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). <i>Nutrients</i> , 2019, 11, 1310.	1.7	54

#	ARTICLE	IF	CITATIONS
145	Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1365-1386.	1.8	167
146	Prader-Willi syndrome: An update on endocrine and metabolic complications. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2019, 20, 239-250.	2.6	58
147	How much does obesity affect the male reproductive function?. <i>International Journal of Obesity Supplements</i> , 2019, 9, 50-64.	12.5	50
148	From gut microbiota dysfunction to obesity: could short-chain fatty acids stop this dangerous course?. <i>Hormones</i> , 2019, 18, 245-250.	0.9	50
149	A rare rarity: Neuroendocrine tumor of the esophagus. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 92-107.	2.0	39
150	The flavor test is a sensitive tool in identifying the flavor sensorineural dysfunction in Parkinson's disease. <i>Neurological Sciences</i> , 2019, 40, 1351-1356.	0.9	11
151	Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. <i>Endocrine</i> , 2019, 66, 417-424.	1.1	25
152	Nutritionist and obesity: brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements. <i>International Journal of Obesity Supplements</i> , 2019, 9, 32-49.	12.5	24
153	Gut microbiota: a new path to treat obesity. <i>International Journal of Obesity Supplements</i> , 2019, 9, 10-19.	12.5	239
154	Taste and the Gastrointestinal tract: from physiology to potential therapeutic target for obesity. <i>International Journal of Obesity Supplements</i> , 2019, 9, 1-9.	12.5	10
155	Health-care inequalities in Italy: challenges for the Government. <i>Lancet Public Health</i> , The, 2019, 4, e605.	4.7	10
156	Sex Differences of Vitamin D Status across BMI Classes: An Observational Prospective Cohort Study. <i>Nutrients</i> , 2019, 11, 3034.	1.7	86
157	Trimethylamine N-oxide, Mediterranean diet, and nutrition in healthy, normal-weight adults: also a matter of sex?. <i>Nutrition</i> , 2019, 62, 7-17.	1.1	91
158	Gender-related issues in the pharmacology of new anti-obesity drugs. <i>Obesity Reviews</i> , 2019, 20, 375-384.	3.1	28
159	Role of Nutrition and Adherence to the Mediterranean Diet in the Multidisciplinary Approach of Hidradenitis Suppurativa: Evaluation of Nutritional Status and Its Association with Severity of Disease. <i>Nutrients</i> , 2019, 11, 57.	1.7	70
160	The lullaby of the sun: the role of vitamin D in sleep disturbance. <i>Sleep Medicine</i> , 2019, 54, 262-265.	0.8	71
161	Human exposure to bisphenol AF and diethylhexylphthalate increases susceptibility to develop differentiated thyroid cancer in patients with thyroid nodules. <i>Chemosphere</i> , 2019, 218, 885-894.	4.2	66
162	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 429-443.	1.2	13

#	ARTICLE	IF	CITATIONS
163	Patient empowerment and the Mediterranean diet as a possible tool to tackle prediabetes associated with overweight or obesity: a pilot study. <i>Hormones</i> , 2019, 18, 75-84.	0.9	37
164	Obesity and sleep disturbance: the chicken or the egg?. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 2158-2165.	5.4	125
165	The management of neuroendocrine tumours: A nutritional viewpoint. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 1046-1057.	5.4	40
166	Could hop-derived bitter compounds improve glucose homeostasis by stimulating the secretion of GLP-1?. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 528-535.	5.4	11
167	SAT-259 Natural History of Anthropometric Parametres of Obesity in Children Affected by X-Linked Hypophosphatemia: Longitudinal Obserbational Study. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	2
168	Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2019, 17, 610-617.	0.8	22
169	Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study. <i>Endokrynologia Polska</i> , 2019, 70, 305-312.	0.3	10
170	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. <i>Calcified Tissue International</i> , 2018, 103, 151-163.	1.5	23
171	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. <i>Endocrine</i> , 2018, 62, 215-233.	1.1	21
172	The effects of hyperprolactinemia and its control on metabolic diseases. <i>Expert Review of Endocrinology and Metabolism</i> , 2018, 13, 99-106.	1.2	30
173	Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study. <i>Endocrine</i> , 2018, 61, 118-124.	1.1	16
174	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	0.6	54
175	Coffee consumption, metabolic syndrome and clinical severity of psoriasis: good or bad stuff?. <i>Archives of Toxicology</i> , 2018, 92, 1831-1845.	1.9	49
176	Obesity and breast cancer in premenopausal women: Current evidence and future perspectives. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 230, 217-221.	0.5	53
177	The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. <i>Endocrine</i> , 2018, 62, 46-56.	1.1	16
178	Gut: A key player in the pathogenesis of type 2 diabetes?. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 1294-1309.	5.4	26
179	The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?. <i>Endocrine</i> , 2018, 60, 15-27.	1.1	22
180	Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 141-154.	1.5	47

#	ARTICLE	IF	CITATIONS
181	Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Jointed French-Italian Retrospective Multicenter Study. <i>Neuroendocrinology</i> , 2018, 106, 264-273.	1.2	14
182	Nutrition, inflammation and liver-spleen axis. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 3141-3158.	5.4	74
183	Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome. <i>Nutrients</i> , 2018, 10, 1971.	1.7	164
184	Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. <i>Nutrients</i> , 2018, 10, 1854.	1.7	61
185	Nutrition and neuroendocrine tumors: An update of the literature. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 159-167.	2.6	38
186	Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome. <i>Nutrition Research Reviews</i> , 2018, 31, 291-301.	2.1	90
187	Heavy Environmental Pressure in Campania and Other Italian Regions: A Short Review of Available Evidence. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 105.	1.2	15
188	Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?. <i>Cancer Treatment Reviews</i> , 2018, 67, 1-9.	3.4	30
189	Nutritional and Environmental Factors in Thyroid Carcinogenesis. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1735.	1.2	50
190	The role of insulin-like growth factor system in the adrenocortical tumors. <i>Minerva Endocrinologica</i> , 2018, 44, 43-57.	1.7	25
191	Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2555.	1.8	23
192	Influence of nutrition on somatotrophic axis: Milk consumption in adult individuals with moderate-severe obesity. <i>Clinical Nutrition</i> , 2017, 36, 293-301.	2.3	47
193	Vitamin D and pancreas: The role of sunshine vitamin in the pathogenesis of diabetes mellitus and pancreatic cancer. <i>Critical Reviews in Food Science and Nutrition</i> , 2017, 57, 3472-3488.	5.4	77
194	Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. <i>Neurosurgical Review</i> , 2017, 40, 105-114.	1.2	51
195	Shedding new light on female fertility: The role of vitamin D. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 273-283.	2.6	98
196	Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 335-346.	2.6	134
197	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. <i>Endocrine</i> , 2017, 58, 349-359.	1.1	77
198	Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 669-678.	1.8	5

#	ARTICLE	IF	CITATIONS
199	Low vitamin D status and obesity: Role of nutritionist. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 215-225.	2.6	116
200	Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 195-205.	2.6	170
201	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 577-589.	1.8	53
202	Selenium supplementation modulates apoptotic processes in thyroid follicular cells. <i>BioFactors</i> , 2017, 43, 415-423.	2.6	22
203	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , 2017, 176, 453-461.	1.9	66
204	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1209-1224.	1.2	14
205	Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance. <i>Endocrinology</i> , 2017, 158, 1527-1532.	1.4	13
206	Vitamin D and cardiovascular disease: From atherosclerosis to myocardial infarction and stroke. <i>International Journal of Cardiology</i> , 2017, 230, 577-584.	0.8	96
207	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. <i>Endocrine</i> , 2017, 57, 539-543.	1.1	10
208	Obesogenic endocrine disruptors and obesity: myths and truths. <i>Archives of Toxicology</i> , 2017, 91, 3469-3475.	1.9	55
209	Accuracy of Fine Needle Cytology in Histological Prediction of Papillary Thyroid Carcinoma Variants: a Prospective Study. <i>Endocrine Pathology</i> , 2017, 28, 187-197.	5.2	5
210	The safety of available treatments options for neuroendocrine tumors. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1149-1161.	1.0	29
211	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , 2017, 24, 495-504.	1.6	61
212	Preliminary results demonstrating the impact of Mediterranean diet on bone health. <i>Journal of Translational Medicine</i> , 2017, 15, 81.	1.8	48
213	Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 1373-1380.	1.8	13
214	Animal models of medullary thyroid cancer: state of the art and view to the future. <i>Endocrine-Related Cancer</i> , 2017, 24, R1-R12.	1.6	29
215	Vitamin D and chronic diseases: the current state of the art. <i>Archives of Toxicology</i> , 2017, 91, 97-107.	1.9	108
216	Phthalates: new cardiovascular health disruptors?. <i>Archives of Toxicology</i> , 2017, 91, 1513-1517.	1.9	29

#	ARTICLE	IF	CITATIONS
217	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. <i>Endocrine</i> , 2017, 56, 633-638.	1.1	30
218	The treatment of hyperinsulinemic hypoglycaemia in adults: an update. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 9-20.	1.8	38
219	Low serum vitamin D-status, air pollution and obesity: A dangerous liaison. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 207-214.	2.6	63
220	Hospitalizations in Pediatric and Adult Patients for All Cancer Type in Italy: The EPIKIT Study under the E.U. COHEIRS Project on Environment and Health. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 495.	1.2	4
221	Reply to the Letter of Terracini B. et al. "Comment on Piscitelli et al. Hospitalizations in Pediatric and Adult Patients for All Cancer Type in Italy: The EPIKIT Study under the E.U. COHEIRS Project on Environment and Health". <i>Int. J. Environ. Res. Public Health</i> 2017, 14, 495. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 1291.	1.2	0
222	Adherence to the Mediterranean Diet and Circulating Levels of Sirtuin 4 in Obese Patients: A Novel Association. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-14.	1.9	48
223	Mediterranean Diet and Phase Angle in a Sample of Adult Population: Results of a Pilot Study. <i>Nutrients</i> , 2017, 9, 151.	1.7	61
224	Multifocality and Hashimoto's thyroiditis as independent predictors of structural recurrence in a cohort of low risk intrathyroidal papillary thyroid cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, e17577-e17577.	0.8	2
225	Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0186508.	1.1	30
226	NutriLive: An Integrated Nutritional Approach as a Sustainable Tool to Prevent Malnutrition in Older People and Promote Active and Healthy Ageing. The EIP-AHA Nutrition Action Group. <i>Advances in Public Health</i> , 2016, 2016, 1-9.	0.7	8
227	CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. <i>Oncotarget</i> , 2016, 7, 18865-18875.	0.8	26
228	Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature. <i>Oncologist</i> , 2016, 21, 875-886.	1.9	15
229	Bioelectrical phase angle and psoriasis: a novel association with psoriasis severity, quality of life and metabolic syndrome. <i>Journal of Translational Medicine</i> , 2016, 14, 130.	1.8	58
230	Osteoporosis across chronic liver disease. <i>Osteoporosis International</i> , 2016, 27, 1967-1977.	1.3	28
231	Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 38-42.	0.6	65
232	Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial. <i>Clinical Endocrinology</i> , 2016, 85, 764-771.	1.2	53
233	Cardiovascular risk in adult hypopituitary patients with growth hormone deficiency: is there a role for vitamin D?. <i>Endocrine</i> , 2016, 52, 111-119.	1.1	48
234	Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis. <i>Journal of Investigative Medicine</i> , 2016, 64, 1025-1034.	0.7	15

#	ARTICLE	IF	CITATIONS
235	Adrenocortical tumors and insulin resistance: What is the first step?. International Journal of Cancer, 2016, 138, 2785-2794.	2.3	29
236	Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis. Bone, 2016, 86, 79-85.	1.4	23
237	Long period fiber grating nano-optrode for cancer biomarker detection. Biosensors and Bioelectronics, 2016, 80, 590-600.	5.3	79
238	Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. Annals of Nuclear Medicine, 2016, 30, 234-241.	1.2	11
239	Low 25 (OH) vitamin D levels are associated with autoimmune thyroid disease in polycystic ovary syndrome. Endocrine, 2016, 53, 538-542.	1.1	26
240	Role of 68Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). Endocrine, 2016, 52, 488-494.	1.1	47
241	Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). Endocrine, 2016, 52, 495-506.	1.1	40
242	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine, 2016, 51, 131-139.	1.1	40
243	Letter to the Editor: Vitamin D: A Wonder Drug for the Cure of Type 2 Diabetes?. Journal of Clinical Endocrinology and Metabolism, 2016, 101, L43-L44.	1.8	3
244	Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. Oncotarget, 2016, 7, 5538-5547.	0.8	30
245	Prognostic role of the <i>CDKN1B</i> V109G polymorphism in multiple endocrine neoplasia type 1. Journal of Cellular and Molecular Medicine, 2015, 19, 1735-1741.	1.6	23
246	Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score. Alimentary Pharmacology and Therapeutics, 2015, 42, 1033-1034.	1.9	1
247	Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. Journal of Translational Medicine, 2015, 13, 303.	1.8	63
248	Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation. Orphanet Journal of Rare Diseases, 2015, 10, 91.	1.2	21
249	Self-Assessment of Adherence to Medication: A Case Study in Campania Region Community-Dwelling Population. Journal of Aging Research, 2015, 2015, 1-6.	0.4	39
250	A Community-Based, Technology-Supported Health Service for Detecting and Preventing Frailty among Older Adults: A Participatory Design Development Process. Journal of Aging Research, 2015, 2015, 1-9.	0.4	45
251	The impact of vitamin D deficiency on patients undergoing kidney transplantation: focus on cardiovascular, metabolic, and endocrine outcomes. Endocrine, 2015, 50, 568-574.	1.1	19
252	Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience. Journal of Endocrinological Investigation, 2015, 38, 1099-1109.	1.8	12

#	ARTICLE	IF	CITATIONS
253	Pituitary function and morphology in Fabry disease. <i>Endocrine</i> , 2015, 50, 483-488.	1.1	5
254	Preliminary data on the relationship between circulating levels of Sirtuin 4, anthropometric and metabolic parameters in obese subjects according to growth hormone/insulin-like growth factor-1 status. <i>Growth Hormone and IGF Research</i> , 2015, 25, 28-33.	0.5	30
255	Advances in therapy of adenomas secreting GH, ACTH and TSH. <i>Nature Reviews Endocrinology</i> , 2015, 11, 73-74.	4.3	5
256	Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas. <i>Neuroendocrinology</i> , 2015, 101, 66-81.	1.2	31
257	Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge. <i>Endocrine</i> , 2015, 50, 824-825.	1.1	7
258	Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet?. <i>Journal of Translational Medicine</i> , 2015, 13, 18.	1.8	112
259	Insulin-Mediated Diseases: Adrenal Mass and Polycystic Ovary Syndrome. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 512-514.	3.1	17
260	Comment on Krul-Poel et al. Effect of Vitamin D Supplementation on Glycemic Control in Patients With Type 2 Diabetes (SUNNY Trial): A Randomized Placebo-Controlled Trial. <i>Diabetes Care</i> 2015;38:1420-1426. <i>Diabetes Care</i> , 2015, 38, e190-e190.	4.3	1
261	Vitamin D and thyroid disease: to D or not to D?. <i>European Journal of Clinical Nutrition</i> , 2015, 69, 291-296.	1.3	71
262	Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 373-374.	1.8	3
263	The evolving field of kinase inhibitors in thyroid cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 60-73.	2.0	30
264	Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells. <i>Scientific World Journal</i> , The, 2014, 2014, 1-13.	0.8	54
265	Intracellular Inactivation of Thyroid Hormone Is a Survival Mechanism for Muscle Stem Cell Proliferation and Lineage Progression. <i>Cell Metabolism</i> , 2014, 20, 1038-1048.	7.2	91
266	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. <i>Endocrine-Related Cancer</i> , 2014, 21, 601-613.	1.6	25
267	Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). <i>European Journal of Endocrinology</i> , 2014, 171, 263-273.	1.9	32
268	Diabetes and Obesity as Independent Risk Factors for Osteoporosis in Postmenopausal Women: A Population Study. <i>European Journal of Inflammation</i> , 2014, 12, 479-487.	0.2	1
269	A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. <i>Gene</i> , 2014, 534, 282-285.	1.0	25
270	Lipid profile in nonobese pregnant women with polycystic ovary syndrome: A prospective controlled clinical study. <i>Steroids</i> , 2014, 88, 36-43.	0.8	57



#	ARTICLE	IF	CITATIONS
271	Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 791-799.	1.8	321
272	Cushing, acromegaly, GH deficiency and tendons. <i>Muscles, Ligaments and Tendons Journal</i> , 2014, 4, 329-332.	0.1	8
273	Increased risk of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a three-year longitudinal study with phalangeal QUS measurements. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2014, 28, 733-41.	0.7	2
274	Pasireotide for the treatment of Cushing's disease. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 557-567.	0.5	2
275	Growth Hormone Replacement Delays the Progression of Chronic Heart Failure Combined With Growth Hormone Deficiency. <i>JACC: Heart Failure</i> , 2013, 1, 325-330.	1.9	57
276	Low 25-Hydroxyvitamin D Levels and Low Bone Density Assessed by Quantitative Ultrasonometry in a Cohort of Postmenopausal Italian Nuns. <i>Journal of Clinical Densitometry</i> , 2013, 16, 308-312.	0.5	6
277	Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. <i>Clinical Endocrinology</i> , 2013, 78, 447-453.	1.2	79
278	Fibrous Variant of Hashimoto's Thyroiditis as a Diagnostic Pitfall in Thyroid Pathology. <i>Case Reports in Endocrinology</i> , 2013, 2013, 1-5.	0.2	10
279	Effect of Cabergoline on Metabolism in Prolactinomas. <i>Neuroendocrinology</i> , 2013, 98, 299-310.	1.2	60
280	Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. <i>Clinical Endocrinology</i> , 2013, 79, 211-216.	1.2	11
281	Polycystic Ovary Syndrome and Hepatic Steatosis: Could Low-Grade Chronic Inflammation Be Mediated by the Spleen?. <i>European Journal of Inflammation</i> , 2013, 11, 179-191.	0.2	4
282	Hashimoto's Thyroiditis and Entero-Chromaffin-like Cell Hyperplasia: Early Detection and Somatostatin Analogue Treatment. <i>European Journal of Inflammation</i> , 2013, 11, 863-870.	0.2	5
283	Insulin sensitivity and early-phase insulin secretion in normoglycemic patients with huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, A43.4-A44.	0.9	0
284	A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease. <i>New England Journal of Medicine</i> , 2012, 366, 914-924.	13.9	550
285	Quality of life in patients with Cushing's disease: a modern approach. <i>Clinical Endocrinology</i> , 2012, 76, 776-777.	1.2	12
286	Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. <i>Pituitary</i> , 2012, 15, 50-58.	1.6	47
287	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 817-23.	1.8	64
288	Medical treatment of prolactinomas. <i>Nature Reviews Endocrinology</i> , 2011, 7, 267-278.	4.3	136

#	ARTICLE	IF	CITATIONS
289	Frontiers in Cancer Endocrinology. <i>Frontiers in Endocrinology</i> , 2011, 2, 7.	1.5	0
290	Diabetes and Cancer. <i>Frontiers in Endocrinology</i> , 2011, 2, 22.	1.5	1
291	Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects. <i>Clinical Endocrinology</i> , 2011, 74, 234-240.	1.2	8
292	Aortic root ectasia in patients with acromegaly: an emerging complication*. <i>Clinical Endocrinology</i> , 2011, 75, 420-421.	1.2	7
293	Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. <i>Journal of Translational Medicine</i> , 2011, 9, 136.	1.8	53
294	Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. <i>European Journal of Endocrinology</i> , 2011, 165, 713-721.	1.9	69
295	Resistance to Somatostatin Analogs in Acromegaly. <i>Endocrine Reviews</i> , 2011, 32, 247-271.	8.9	220
296	Therapy of aggressive pituitary tumors. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1561-1570.	0.9	57
297	Spleen: A new role for an old player?. <i>World Journal of Gastroenterology</i> , 2011, 17, 3776.	1.4	104
298	Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. <i>BMC Endocrine Disorders</i> , 2010, 10, 10.	0.9	48
299	Dose optimization of somatostatin analogues for acromegaly patients. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 125-127.	1.8	6
300	Somatostatin Analogues: Treatment of Pituitary and Neuroendocrine Tumors. <i>Progress in Brain Research</i> , 2010, 182, 281-294.	0.9	28
301	A Reappraisal of Diagnosing GH Deficiency in Adults: Role of Gender, Age, Waist Circumference, and Body Mass Index. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4414-4422.	1.8	63
302	Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2907-2914.	1.8	52
303	Impact of Somatostatin Analogs Versus Surgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 528-537.	1.8	51
304	Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3746-3756.	1.8	132
305	Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. <i>Acta Diabetologica</i> , 2009, 46, 85-95.	1.2	119
306	Medical therapy of pituitary adenomas: Effects on tumor shrinkage. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2009, 10, 111-123.	2.6	51

#	ARTICLE	IF	CITATIONS
307	Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. <i>Clinical Endocrinology</i> , 2009, 70, 757-768.	1.2	108
308	Significant tumour shrinkage after 12 months of lanreotide Autogel 120µg treatment given first-line in acromegaly. <i>Clinical Endocrinology</i> , 2009, 71, 237-245.	1.2	64
309	The prolactinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 575-596.	2.2	130
310	5 Long-term acromegaly and associated cardiovascular complications: a case-based review. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, S31-S38.	2.2	13
311	The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 223-230.	1.8	297
312	Medical consequences of acromegaly: What are the effects of biochemical control?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2008, 9, 21-31.	2.6	31
313	The accuracy of the arginine growth hormone test in Parkinsonism. <i>Movement Disorders</i> , 2008, 23, 1331-1331.	2.2	0
314	Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. <i>Clinical Endocrinology</i> , 2008, 68, 66-71.	1.2	120
315	GH and IGF-1 excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. <i>Clinical Endocrinology</i> , 2008, 69, 613-620.	1.2	37
316	The GH-IGF-1 axis and the cardiovascular system: clinical implications. <i>Clinical Endocrinology</i> , 2008, 69, 347-358.	1.2	178
317	Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. <i>Human Reproduction</i> , 2008, 23, 642-650.	0.4	197
318	Body fat in men with prolactinoma. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 985-990.	1.8	22
319	Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. <i>European Journal of Endocrinology</i> , 2008, 159, 389-397.	1.9	93
320	Increased Prevalence of Tricuspid Regurgitation in Patients with Prolactinomas Chronically Treated with Cabergoline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3777-3784.	1.8	154
321	No Greater Incidence or Worsening of Cardiac Valve Regurgitation with Somatostatin Analog Treatment of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2243-2248.	1.8	28
322	Impact of Treating Acromegaly First with Surgery or Somatostatin Analogs on Cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2639-2646.	1.8	78
323	Growth Hormone Treatment on Atherosclerosis: Results of a 5-Year Open, Prospective, Controlled Study in Male Patients with Severe Growth Hormone Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3416-3424.	1.8	57
324	Growth Hormone-Secreting Tumor Shrinkage after 3 Months of Octreotide-Long-Acting Release Therapy Predicts the Response at 12 Months. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3436-3442.	1.8	32

#	ARTICLE	IF	CITATIONS
325	Medical therapy for clinically non-functioning pituitary adenomas. <i>Endocrine-Related Cancer</i> , 2008, 15, 905-915.	1.6	152
326	The Association of Fasting Insulin Concentrations and Colonic Neoplasms in Acromegaly: A Colonoscopy-Based Study in 210 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3854-3860.	1.8	56
327	Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2007, 157, 579-587.	1.9	77
328	Beneficial Effects of a Three-Month Structured Exercise Training Program on Cardiopulmonary Functional Capacity in Young Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1379-1384.	1.8	172
329	A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 497-506.	1.8	20
330	Pegvisomant in acromegaly: Why, when, how. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 693-699.	1.8	35
331	Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. <i>Clinical Endocrinology</i> , 2007, 66, 714-722.	1.2	28
332	Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. <i>Clinical Endocrinology</i> , 2007, 67, 426-433.	1.2	97
333	Body fat in nonobese women with prolactinoma treated with dopamine agonists. <i>Clinical Endocrinology</i> , 2007, 67, 845-852.	1.2	40
334	The importance of presurgical somatostatin analogue therapy in acromegaly. <i>Endokrynologia Polska</i> , 2007, 58, 356-60.	0.3	4
335	First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment) Tj ETQq1 1 0.784314 rgBT /Overl Endocrinological Investigation, 2006, 29, 1017-1020.	1.8	43
336	Cardiovascular risk in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2006, 86, S20-S21.	0.5	58
337	Beginning to end: Cardiovascular implications of growth hormone (GH) deficiency and GH therapy. <i>Growth Hormone and IGF Research</i> , 2006, 16, 41-48.	0.5	72
338	The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. <i>Clinical Endocrinology</i> , 2006, 64, 307-313.	1.2	56
339	First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. <i>Clinical Endocrinology</i> , 2006, 64, 342-351.	1.2	69
340	Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. <i>Clinical Endocrinology</i> , 2006, 65, 250-256.	1.2	42
341	Cardiopulmonary Impairment in Young Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2967-2971.	1.8	70
342	The Natural History of Partial Growth Hormone Deficiency in Adults: A Prospective Study on the Cardiovascular Risk and Atherosclerosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2191-2200.	1.8	38

#	ARTICLE	IF	CITATIONS
343	Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. <i>European Journal of Endocrinology</i> , 2006, 154, 467-477.	1.9	148
344	Advances in the Treatment of Prolactinomas. <i>Endocrine Reviews</i> , 2006, 27, 485-534.	8.9	707
345	Predictors of Tumor Shrinkage after Primary Therapy with Somatostatin Analogs in Acromegaly: A Prospective Study in 99 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2112-2118.	1.8	116
346	Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006, 2, 200-210.	2.9	55
347	Partial Surgical Removal of Growth Hormone-Secreting Pituitary Tumors Enhances the Response to Somatostatin Analogs in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 85-92.	1.8	178
348	Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. <i>Clinical Endocrinology</i> , 2005, 63, 342-349.	1.2	25
349	Improvement in Endothelial Structure and Function after Metformin Treatment in Young Normal-Weight Women with Polycystic Ovary Syndrome: Results of a 6-Month Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6072-6076.	1.8	129
350	Common Carotid Intima-Media Thickness in Growth Hormone (GH)-Deficient Adolescents: A Prospective Study after GH Withdrawal and Restarting GH Replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2659-2665.	1.8	41
351	Short-Term Effects of Growth Hormone (GH) Treatment or Deprivation on Cardiovascular Risk Parameters and Intima-Media Thickness at Carotid Arteries in Patients with Severe GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2056-2062.	1.8	55
352	Does a Gender-Related Effect of Growth Hormone (GH) Replacement Exist on Cardiovascular Risk Factors, Cardiac Morphology, and Performance and Atherosclerosis? Results of a Two-Year Open, Prospective Study in Young Adult Men and Women with Severe GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5146-5155.	1.8	45
353	Growth Hormone/Insulin-Like Growth Factor-1 System and Connective Tissues: Basic Aspects and Clinical Implications. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 29-42.	0.8	8
354	Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 440-448.	1.8	63
355	The Increase of Leukocytes as a New Putative Marker of Low-Grade Chronic Inflammation and Early Cardiovascular Risk in Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2-5.	1.8	212
356	Severe systemic complications of acromegaly. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 65-77.	1.8	12
357	The acromegalic arthropathy. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 24-31.	1.8	19
358	New perspectives in the medical treatment of acromegaly. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 58-66.	1.8	2
359	The Severity of Growth Hormone Deficiency Correlates with the Severity of Cardiac Impairment in 100 Adult Patients with Hypopituitarism: An Observational, Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5998-6004.	1.8	101
360	Prolactin and Prostate Hypertrophy: A Pilot Observational, Prospective, Case-Control Study in Men with Prolactinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2770-2775.	1.8	26

#	ARTICLE	IF	CITATIONS
361	Early Impairment of Endothelial Structure and Function in Young Normal-Weight Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4588-4593.	1.8	310
362	The heart: an end-organ of GH action. <i>European Journal of Endocrinology</i> , 2004, 151 Suppl 1, S93-101.	1.9	80
363	Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency. <i>Clinical Endocrinology</i> , 2004, 61, 360-366.	1.2	44
364	Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1704-1711.	1.8	200
365	Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. <i>Endocrine Reviews</i> , 2004, 25, 102-152.	8.9	1,093
366	Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?. <i>Reproductive BioMedicine Online</i> , 2004, 9, 505-510.	1.1	66
367	The Cardiovascular Risk of Young Women with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3696-3701.	1.8	250
368	Cardiovascular Effects of Growth Hormone Treatment: Potential Risks and Benefits. <i>Hormone Research in Paediatrics</i> , 2004, 62, 42-50.	0.8	9
369	Somatostatin Analogs in Treatment of Non-Growth Hormone-Secreting Pituitary Adenomas. <i>Endocrine</i> , 2003, 20, 279-284.	2.2	36
370	Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. <i>Clinical Endocrinology</i> , 2003, 58, 169-176.	1.2	99
371	Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia. <i>New England Journal of Medicine</i> , 2003, 349, 2023-2033.	13.9	310
372	High Prevalence of Cardiac Valve Disease in Acromegaly: An Observational, Analytical, Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3196-3201.	1.8	119
373	Influence of Growth Hormone on Cardiovascular Health and Disease. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2003, 2, 347-356.	1.8	5
374	Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. <i>European Journal of Endocrinology</i> , 2003, 148, 325-331.	1.9	203
375	Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. <i>European Journal of Endocrinology</i> , 2003, 148, 31-38.	1.9	55
376	Effect of Growth Hormone (GH) and/or Testosterone Replacement on the Prostate in GH-Deficient Adult Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 88-94.	1.8	29
377	The treatment algorithm of acromegaly. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 39-45.	1.8	5
378	The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 53-6.	1.8	4

#	ARTICLE	IF	CITATIONS
379	Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2002, 146, 303-309.	1.9	63
380	The Cardiovascular Risk of GH-Deficient Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3650-3655.	1.8	104
381	Dopamine receptor agonists for treating prolactinomas. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 787-800.	1.9	112
382	The Cardiovascular Risk of Adult GH Deficiency (GHD) Improved after GH Replacement and Worsened in Untreated GHD: A 12-Month Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1088-1093.	1.8	99
383	Cardiovascular Consequences of Early-Onset Growth Hormone Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3097-3104.	1.8	82
384	Lymphocyte subset pattern in acromegaly. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 125-128.	1.8	21
385	Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushing's disease. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 142-151.	1.8	21
386	Very delayed hyponatremia after surgery and radiotherapy for a pituitary macroadenoma. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 163-168.	1.8	11
387	Gender- and age-related differences in the endocrine parameters of acromegaly. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 532-538.	1.8	64
388	<sup>99m</sup> Tc pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. <i>Clinical Endocrinology</i> , 2002, 56, 713-721.	1.2	7
389	Is the impact of GH deficiency on the heart dependent on time of onset?. <i>International Journal of Clinical Practice</i> , Supplement, 2002, , 27-31.	0.3	0
390	In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 522-528.	1.8	20
391	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. <i>Clinical Endocrinology</i> , 2001, 54, 97-106.	1.2	7
392	Growth hormone and the heart. <i>Clinical Endocrinology</i> , 2001, 54, 137-154.	1.2	328
393	Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. <i>Clinical Endocrinology</i> , 2001, 54, 515-524.	1.2	101
394	Are patients with acromegaly at high risk for dysrhythmias?. <i>Clinical Endocrinology</i> , 2001, 55, 305-306.	1.2	24
395	Cardiovascular complications in acromegaly: methods of assessment. <i>Pituitary</i> , 2001, 4, 251-257.	1.6	25
396	Spine abnormalities and damage in patients cured from Cushing's disease. <i>Pituitary</i> , 2001, 4, 153-161.	1.6	31

#	ARTICLE	IF	CITATIONS
397	Uncommon clinical course of multiple osteochondromatosis in a patient with a long-term history of Cushing's disease. <i>Pituitary</i> , 2001, 4, 187-193.	1.6	1
398	Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. <i>European Journal of Endocrinology</i> , 2001, 144, 499-507.	1.9	128
399	Usefulness of Different Biochemical Markers of the Insulin-Like Growth Factor (IGF) Family in Diagnosing Growth Hormone Excess and Deficiency in Adults <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3001-3008.	1.8	84
400	Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease. <i>European Journal of Endocrinology</i> , 2000, 143 Suppl 1, S35-S42.	1.9	8
401	Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. <i>Clinical Endocrinology</i> , 2000, 52, 319-327.	1.2	91
402	Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with <sup>123</sup> I-methoxybenzamide. <i>Clinical Endocrinology</i> , 2000, 52, 437-445.	1.2	52
403	The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. <i>Clinical Endocrinology</i> , 2000, 53, 53-60.	1.2	77
404	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. <i>Clinical Endocrinology</i> , 2000, 53, 13-19.	1.2	52
405	Systemic Hypertension and Impaired Glucose Tolerance Are Independently Correlated to the Severity of the Acromegalic Cardiomyopathy <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 193-199.	1.8	154
406	Recombinant Growth Hormone (GH) Therapy in GH-Deficient Adults: A Long-Term Controlled Study on Daily Versus Thrice Weekly Injections. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3720-3725.	1.8	57
407	Muscle Sympathetic Nerve Activity in Patients with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3203-3207.	1.8	14
408	Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. <i>European Journal of Endocrinology</i> , 2000, 143, 61-69.	1.9	16
409	Cabergoline. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 555-574.	0.9	67
410	Hormonal and seminal evaluation of Leydig cell tumour patients before and after orchiectomy. <i>Andrologia</i> , 2000, 32, 147-154.	1.0	0
411	Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1919-1924.	1.8	166
412	Persistence of Increased Cardiovascular Risk in Patients with Cushing's Disease after Five Years of Successful Cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2664-2672.	1.8	344
413	The Growth Hormone (GH) Response to the Arginine Plus GH-Releasing Hormone Test Is Correlated to the Severity of Lipid Profile Abnormalities in Adult Patients with GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1277-1282.	1.8	93
414	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1986-1991.	1.8	67



#	ARTICLE	IF	CITATIONS
415	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. <i>Pituitary</i> , 1999, 1, 115-120.	1.6	81
416	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. <i>Clinical Endocrinology</i> , 1998, 49, 77-84.	1.2	13
417	Prostatic Hyperplasia: An Unknown Feature of Acromegaly. <i>Journal of Urology</i> , 1998, 160, 1583-1584.	0.2	0
418	Treatment of prolactinomas. <i>Annals of Medicine</i> , 1998, 30, 452-459.	1.5	63
419	Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing's disease before and after corticotropin-releasing hormone administration. <i>Journal of Endocrinological Investigation</i> , 1998, 21, 257-262.	1.8	4
420	Impairment of Bone Status in Patients with Central Diabetes Insipidus*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2275-2280.	1.8	24
421	Failure of long-term therapy with sodium valproate in Cushing's disease. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 387-392.	1.8	33
422	Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. <i>Clinical Endocrinology</i> , 1997, 47, 23-28.	1.2	89
423	Vasopressin levels in Cushing's disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing's disease. <i>Clinical Endocrinology</i> , 1996, 45, 157-166.	1.2	11
424	Prediction of efficacy of octreotide therapy in patients with acromegaly.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2356-2362.	1.8	126
425	Impaired luteinizing hormone responsiveness to gonadotropin-releasing hormone in the inferior petrosal sinuses of hyperprolactinemic patients. <i>Gynecological Endocrinology</i> , 1995, 9, 15-21.	0.7	7
426	RAPID AND LONG-LASTING SUPPRESSION OF PROLACTIN SECRETION AND SHRINKAGE OF PROLACTINOMAS AFTER INJECTION OF LONG-ACTING REPEATABLE FORM OF BROMOCRIPTINE (PARLODEL LAR). <i>Clinical Endocrinology</i> , 1990, 33, 161-170.	1.2	35
427	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. , 0, .		23
428	Early Vascular Alterations in Acromegaly. , 0, .		20
429	Adherence to the Mediterranean Diet as a Modifiable Risk Factor for Thyroid Nodular Disease and Thyroid Cancer: Results From a Pilot Study. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	7